Neutralizing monoclonal antibody against human dll4
AssigneeSmart Targeting Limited
InventorsMakoto Sunamura, Hideo Yagita
Life of this patent
Estimating the term…
Abstract
The present invention provides a binding protein capable of binding to DLL4 as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.
Claims34
A binding protein capable of binding to human DLL4, which binding protein comprises at least one CDR domain selected from
- (a) a light chain CDR 1 comprising the amino acid sequence RASSSVSFMH (SEQ ID NO;
- 6), or a sequence substantially homologous thereto;
- (b) a light chain CDR 2 comprising the amino acid sequence ATSNLTS (SEQ ID NO:
- 7), or a sequence substantially homologous thereto;
- (c) a light chain CDR3 comprising the amino acid sequence QQWSSNPFT (SEQ ID NO:
- 8), or a sequence substantially homologous thereto;
- (d) a heavy chain CDR1 comprising the amino acid sequence SYVMH (SEQ ID NO. 3), or a sequence substantially homologous thereto;
- (e) a heavy chain CDR2 comprising the amino acid sequence YIIPYNDGTKYNEKFKG (SEQ ID NO. 4), or a sequence substantially homologous thereto;
- and
- (f) a heavy chain CDR3 comprising the amino acid sequence SEDYDHFDY (SEQ ID NO:
- 5), or a sequence substantially homologous thereto.
(canceled)
(canceled)
(canceled)
(canceled)
A method according to claim 34, wherein said disorder or condition is selected from prostate cancer and pancreatic cancer.
Dependencies are inferred from the claim text.